U.S. BIOTECH SEEKS APPROVAL FOR HIV DRUG IN NIGERIA, KENYA

Amazon Biotech has announced it is in negotiations with a European company to obtain approvals for sale of its HIV drug in Nigeria and Kenya.

"Obtaining these licenses will be an important step for the company. We believe that our drug will have a positive impact on the AIDS epidemic in Africa," Mechael Kanovsky, president of the company, said.

In October Amazon announced it had developed a next-generation HIV treatment that includes both immune modulator functions and antiviral activity. This formulation, based on the company's investigational drug AMZ0026, includes active ingredients derived from a plant known to possess antiviral properties.

The company plans to begin Phase I/II clinical studies of AMZ0026 in the near future, with a goal conducting Phase III trials under a joint venture with a major pharmaceutical company.

Amazon specializes in natural plant pharmaceuticals with a focus on immune modulator drugs. AMZ0026 is the company's first such drug.